Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Director Declaration

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
12,950.00    -404.00 (-3.03%)
Bid:
12,948.00
Ask:
12,952.00
Spread: 4.00 (0.031%)
Market Cap: £200.84b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Director Declaration

16 Jul 2020 07:00

RNS Number : 1169T
AstraZeneca PLC
16 July 2020
 

16 July 2020 07:00 BST

 

 

Director Declaration

 

AstraZeneca PLC (the Company) today announced that Pascal Soriot, Chief Executive Officer of the Company, has been appointed as an independent Non-Executive Director of CSL Limited (ASX:CSL; USOTC:CSLLY), to be effective from 19 August 2020.

 

This announcement is made pursuant to Listing Rule 9.6.14 R (2).

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNXELFFBDLZBBX
789101112131415
Date   Source Headline
24th Jun 20217:00 amRNSLynparza approved in China for prostate cancer
23rd Jun 20217:00 amRNSOrpathys approved in China for lung cancer
22nd Jun 20217:00 amRNSKoselugo approved in the EU for children with NF1
15th Jun 20217:00 amRNSUpdate on AZD7442 STORM CHASER trial
10th Jun 202111:32 amRNSStabilisation Notice
7th Jun 20217:00 amRNSCalquence head-to-head results versus ibrutinib
4th Jun 20217:05 amRNSLynparza reduced recurrence risk in breast cancer
4th Jun 20217:00 amRNSAstraZeneca appoints new Chief Financial Officer
2nd Jun 20217:00 amRNSPublication of Final Terms
1st Jun 20213:01 pmRNSBlock listing Interim Review
1st Jun 20213:00 pmRNSTotal Voting Rights
28th May 20217:00 amRNSTagrisso approved in EU in early lung cancer
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20217:00 amRNSAstraZeneca prices a EUR800m bond offering
26th May 20219:24 amRNSStabilisation Notice
26th May 20217:00 amRNSAstraZeneca prices a $7bn bond offering
25th May 20217:00 amRNSEMTN programme update - publication of Prospectus
21st May 20217:00 amRNSVaxzevria COVID-19 vaccine approved in Japan
18th May 20213:30 pmRNSDirector/PDMR Shareholding
11th May 20212:00 pmRNSResult of AGM
11th May 20211:55 pmRNSShareholders vote in favour of Alexion acquisition
7th May 20217:00 amRNSImfinzi + tremelimumab showed survival in POSEIDON
5th May 20216:30 pmRNSHolding(s) in Company
4th May 20213:00 pmRNSTotal Voting Rights
4th May 20217:00 amRNSFarxiga approved in the US for CKD
30th Apr 20217:00 amRNSAZN: First quarter 2021 results
26th Apr 20217:10 amRNSSelumetinib recommended for EU approval in NF1
26th Apr 20217:05 amRNSTagrisso adjuvant receives positive CHMP opinion
26th Apr 20217:00 amRNSNirsevimab Phase III trial met primary endpoint
16th Apr 202112:00 pmRNSUS clearance of proposed acquisition of Alexion
14th Apr 20217:00 amRNSTagrisso approved in China in early lung cancer
12th Apr 20211:00 pmRNSCircular and notice of general meeting
12th Apr 20217:00 amRNSUpdate on Farxiga COVID-19 DARE-19 Phase III trial
1st Apr 20213:00 pmRNSTotal Voting Rights
30th Mar 202112:15 pmRNSNotice of AGM
25th Mar 20213:00 pmRNSDirector/PDMR Shareholding
25th Mar 20217:00 amRNSAZD1222 US Ph3 primary analysis confirms efficacy
22nd Mar 20217:00 amRNSAstraZeneca US vaccine trial met primary endpoint
16th Mar 20217:05 amRNSDivestment of Viela shareholding completed
16th Mar 20217:00 amRNSUS supply agreement for additional AZD7442 doses
9th Mar 20213:00 pmRNSDirector/PDMR Shareholding
4th Mar 20213:00 pmRNSDesignation of EU home member state
3rd Mar 20217:00 amRNSUS court decision favours Symbicort patents
2nd Mar 20217:00 amRNSFurther update on roxadustat US regulatory review
1st Mar 20213:00 pmRNSTotal Voting Rights
22nd Feb 20217:00 amRNSVoluntary withdrawal Imfinzi US bladder indication
17th Feb 20217:00 amRNSLynparza: IDMC recommend early analysis of OlympiA
16th Feb 202111:15 amRNSFiling of Form 20-F with SEC
15th Feb 20213:00 pmRNSDirector/PDMR Shareholding
789101112131415

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
SST
Scottish Oriental Smaller Companies Trust
LSE
1.12%
STCK
STCK.L
LSE
0.00%
AV.
Aviva
LSE
0.46%
HWG
Harworth Gp
LSE
-0.96%
ZTF
Zotefoams Plc
LSE
-0.56%
Trending
EZJ
easyJet
LSE
14.55%
CPI
Capita
LSE
3.62%
GST
GSTechnologies
LSE
4.04%
QED
Quadrise
LSE
0.61%
FORG
Forgent
LSE
-6.25%